Real-world evidence

End-to-end support to accelerate approval, access and adoption in obesity

Integrated global obesity therapy development and commercialization

The obesity drug market is advancing quickly, and expectations are rising just as fast. Sponsors must execute efficiently on a global scale while generating the evidence regulators, payers, providers and patients expect.

The PPD™ clinical research business of Thermo Fisher Scientific brings clinical development, global laboratory services, and real-world evidence together into a coordinated strategy that reduces operational risk and supports approval, reimbursement, and long-term asset performance.

Early clinical development
Enable earlier, data-driven go/no-go decisions and accelerate timelines through high-compliance recruitment in dedicated clinical research units (CRUs).

Pivotal trials
Support adherence, retention, and endpoint integrity to minimize protocol deviations and protect study outcomes.

Global laboratory services
Deliver consistent and comprehensive metabolic and safety testing through a harmonized global lab network, including China.

Site and patient network
Accelerate enrollment through prioritized sites and established, supported assets.



Global clinical supply chain
Minimize supply chain disruptions, reduce regulatory risk and ensure uninterrupted distribution.

Market access
Generate evidence aligned to payer expectations to support pricing and reimbursement decisions.

Post-approval evidence
Demonstrate long-term effectiveness, safety, and adherence in chronic-use obesity therapies.

Lifecycle optimization
Support differentiation, expansion and sustained value through strategic evidence generation.

Proven experience and integrated capabilities that drive obesity trial success

- **36 Phase I–IV obesity studies completed** in the past 5 years, enrolling 10,000+ patients, including 22 GLP-1 studies
- **Centralized, in-house dietitian services** supporting adherence and sustained weight management
- **Digital and patient engagement solutions** reducing burden, promoting participation and improving data completeness
- **Medical communications patient navigator services** improving engagement, adherence and retention
- **Global laboratory services** supporting metabolic and safety testing across 3500+ sites in 69 countries

The PPD CorEvitas Obesity Registry

Real-world evidence to de-risk, differentiate and extend value

Chronic use of obesity medications and intensifying market competition are increasing payer scrutiny and raising the bar for differentiation beyond short-term weight loss and GI tolerability, requiring proof of durability, persistence and economic value.

The **PPD™ CorEvitas™ Obesity Registry** is a prospective platform that combines regulatory-grade clinical outcomes with one of the most comprehensive obesity patient experience and preference datasets. It integrates patient reported outcomes (PROs), health-related quality of life (HRQoL), preference, adherence, and persistence measures to strengthen regulatory positioning, payer value demonstration, and long-term asset performance.

The right solution makes the difference

- ☑ Prospective design (not retrospective electronic medical records)
- ☑ Regulatory-grade clinical and safety outcomes
- ☑ Integrated patient-experience and preference data
- ☑ Advanced obesity-specific PRO and clinical outcome assessment (COA) expertise

One registry. Continuous lifecycle insight.

Early Phase

Design smarter

- Identify high-value subpopulations
- Detect early safety and tolerability signals
- Link biomarkers and PROs to persistence
- Model uptake and discontinuation risk

Phase II–III

De-risk pivotal investment

- Align eligibility and endpoints with real-world practice
- Enrich likely responders
- Select endpoints that support differentiation and access

Late Phase & Post-Approval

Prove and defend value

- Demonstrate durable real-world effectiveness
- Quantify value beyond weight loss
- Strengthen payer and HTA submissions with model-ready inputs

Learn more at **ppd.com/rwd**